Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 1;35(1):2.
doi: 10.1007/s12032-017-1062-7.

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Alessandro Del Gobbo  1 , Annamaria Morotti  1   2 , Anna Eleonora Colombo  1 , Valentina Vaira  1   2 , Giulia Ercoli  1 , Chiara Pesenti  1   2 , Eleonora Bonaparte  1 , Elena Guerini-Rocco  3   4 , Andrea Di Cristofori  5 , Marco Locatelli  5 , Alessandro Palleschi  6 , Stefano Ferrero  7   8
Affiliations

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Alessandro Del Gobbo et al. Med Oncol. .

Abstract

Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

Keywords: Brain metastasis; IMP3; Microarray; NSCLC.

PubMed Disclaimer

References

    1. Hum Pathol. 2010 Apr;41(4):477-84 - PubMed
    1. J Neurooncol. 2005 Oct;75(1):5-14 - PubMed
    1. J Biol Chem. 2005 May 6;280(18):18517-24 - PubMed
    1. Br J Cancer. 2003 Mar 24;88(6):887-94 - PubMed
    1. EMBO J. 2006 Apr 5;25(7):1456-68 - PubMed

MeSH terms

LinkOut - more resources